Catalent Pharma Solutions, a global provider of advanced delivery technologies and development offerings for drugs, biologics and consumer health products, has expanded its primary packaging capabilities at its clinical facility in Shanghai, China, which have reached the commissioning stage with completion scheduled by the end of 2018.
The expansion includes a new automated, high-speed bottling line suitable for capsule and tablet products. The line will increase packaging capacity by up to 100 bottles/min, providing quick and easy changeover that’s essential for clinical-scale production.
“Globally, almost 2,000 industry-sponsored clinical trials were conducted in the last two years,” says Roel de Nobel, Catalent’s Vice President, Global Operations, Clinical Supply Services. “Our continued investment in Asia Pacific reflects the importance of, and the continued growth of clinical trials in Asia, driving the need for in-region packaging services.”
This expansion follows the announcement that work is underway to open a new clinical facility outside of Shanghai’s free trade zone (FTZ). The new facility is expected to be completed in early 2019 and will join the company’s existing three clinical packaging facilities in the Asia Pacific region: Shanghai’s Waigaoqiao FTZ, Singapore and Kakegawa, Japan.
In addition to its primary packaging capabilities, the company offers comprehensive clinical supply solutions in the region including clinical supply management, comparator sourcing, FastChain® demand led supply, secondary packaging, storage and global distribution and clinical returns and destruction.
